Oculis Holding (OCS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.16
- Estimate
- -$0.38
- Surprise
- +57.8%
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Oculis Holding (OCS) reported a narrower loss than forecast — diluted EPS of -$0.16 against the -$0.38 estimate (a 57.8% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates OCS Sell at 4.9/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +57.8% surprise compares with a +14.6% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $35.77 vs price $10.56 — ratio 3.4×). Rejected, falling back to technical TP.
- Quality below floor (1.9 < 4.0)
- Momentum score 2.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.56
- Price target
- $13.43
- Stop
- $10.19
- Upside to target
- +27.2%
Risk check: RSI 9 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
OCS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $586.4M
- P/E (fwd)
- -5.2
- 52-week range
- $10.50–$34.48
- Off 52-week high
- 69.4%
- RSI (14)
- 9
- Volume vs avg
- 1.40×
- Score today
- 4.9/10